Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 24 Kidney Neoplasms 8 von Hippel-Lindau Disease 5 Parkinson Disease 4, Autosomal Dominant Lewy Body 5 Pheochromocytoma 2 Paraganglioma 2 Neoplasm Metastasis 2 Vulvar Neoplasms 1 Vaginal Neoplasms 1 Uterine Neoplasms 1 Uterine Cervical Neoplasms 1 Recurrence 1 Prostatic Neoplasms 1 Ovarian Neoplasms 1 Neuroectodermal Tumors, Primitive 1 Neoplasms 1 Metastatic Castration-Resistant Prostate Cancer 1 Hemangioblastoma 1 Glioblastoma 1 Endometrial Neoplasms 1 Clear-cell metastatic renal cell carcinoma 1 Carcinoma 1 Breast Neoplasms 1 Adenoma, Islet Cell 1

Interventions

Cyclophosphamide 153 Dexamethasone 141 Rituximab 85 fludarabine 79 Lenalidomide 72 Cytarabine 70 Bortezomib 64 fludarabine phosphate 63 Gemcitabine 62 venetoclax 54 Etoposide 53 pomalidomide 52 pembrolizumab 52 Paclitaxel 48 Cisplatin 48 Carboplatin 48 Peripheral Blood Stem Cell Transplantation 47 Filgrastim 40 Radiotherapy 39 Busulfan 37 Calcium Dobesilate 36 Methotrexate 34 Melphalan 34 Bevacizumab 33 carfilzomib 32 Cyclosporine 32 Azacitidine 32 Mycophenolic Acid 30 Vincristine 29 Bendamustine Hydrochloride 29

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Recurrence × belzutifan × Clear all

NCT03634540 2024-12-20

MK-6482-003

Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Phase 2 Active not recruiting

Carcinoma, Renal Cell, Kidney Neoplasms, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡